Ongoing, recruitingTherapeutic exploratory (Phase II)Interventional

A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination with Gemcitabine in Patients with Advanced or Metastatic Cancer with a Focus on Ovarian Cancer

At a glance

Status

Ongoing, recruiting

Phase

Therapeutic exploratory (Phase II)

Sponsor

Esperas Pharma Inc., Esperas Pharma Inc.

Enrolment target

Start

28 Aug 2023

Safety (treatment emergent adverse events, serious adverse events, and clinical abnormalities per Common Terminology Criteria for Adverse Event)

Age 18 Years to any · Sex: Female

Always speak to your GP or specialist before deciding to take part in a study.